Most people associate liver disease with fat. Yet for carriers of the minor A allele at rs4841132, the primary problem begins one step earlier in liver metabolism: the regulation of glycogen¹¹ glycogen
The body's main short-term glucose storage molecule. The liver stores glycogen and releases glucose into the blood between meals to maintain stable blood sugar levels synthesis and breakdown. This variant is in complete linkage disequilibrium²² linkage disequilibrium
LD: the tendency of nearby genetic variants to be inherited together. Two SNPs in complete LD are interchangeable genetic markers for the same underlying biological signal with rs4240624, and the two positions tag the same PPP1R3B signal. The landmark Stender 2018 study (n=112,428) used rs4841132 as the primary tagging SNP, making it the most directly-cited variant for this locus in the literature.

PPP1R3B encodes a regulatory subunit of protein phosphatase 1 (PP1), a master switch that governs glycogen synthesis and breakdown in the liver. The A allele at rs4841132 — carried by roughly 9% of Europeans and up to 20% of people of Latino ancestry — influences how much glycogen the liver stores, pushing the balance toward accumulation. The downstream effects extend beyond glycogen: elevated liver enzymes, increased hepatic glycogenosis susceptibility, and a meaningful increase in gallstone risk have all been documented across large population studies.

The Mechanism

Protein phosphatase 1³³ Protein phosphatase 1
PP1: one of the most abundant phosphatases in the body, involved in glycogen metabolism, muscle contraction, protein synthesis, and many other processes. Its activity is tightly regulated by dozens of binding proteins (PP1) is a central regulator of glycogen metabolism. PPP1R3B acts as a glycogen-targeting subunit that directs PP1 to two key enzymes: glycogen synthase (which builds glycogen) and glycogen phosphorylase (which breaks it down). By activating glycogen synthase and inhibiting glycogen phosphorylase, PPP1R3B tips the liver toward glycogen storage.

The rs4841132 A allele is a near-gene regulatory variant — annotated as a non-coding transcript variant affecting the LOC157273 lncRNA locus adjacent to PPP1R3B — that increases PPP1R3B activity or expression. Mouse studies confirm the mechanism directly: overexpression of PPP1R3B causes hepatic glycogen accumulation and elevated plasma ALT, while knockouts produce glycogen-deficient livers. In humans, the minor A allele is associated with increased hepatic X-ray attenuation — a hallmark of glycogen loading — and elevated liver enzymes across the large Stender 2018 cohort.

Importantly, the excess glycogen from this variant does not appear to directly increase hepatic triglyceride content. This distinguishes the PPP1R3B signal from the well-known PNPLA3 rs738409 variant, which directly promotes liver fat accumulation. Instead, the effect reflects hepatic glycogenosis⁴⁴ hepatic glycogenosis
Abnormal glycogen accumulation in the liver. Can cause hepatomegaly and elevated liver enzymes, and is associated with metabolic syndrome even in the absence of excess fat, a condition independently harmful even without steatosis.

Because rs4841132 and rs4240624 are in complete LD, they measure the same biological effect. Individuals genotyped at either position carry the same functional risk information. rs4841132 is included in the GeneOps database because it is the primary rsid analyzed in the Stender 2018 landmark study and is present on chip platforms where rs4240624 may not be represented.

The Evidence

The foundational work comes from Stender et al. 2018⁵⁵ Stender et al. 2018
Stender S, Smagris E, et al. "Relationship between genetic variation at PPP1R3B and levels of liver glycogen and triglyceride." Hepatology, 2018, which analyzed 112,428 participants across three large cohorts. The minor A allele at rs4841132 showed consistent ALT elevation (P = 3×10⁻⁴ in the Copenhagen cohort; P = 0.004 in the Dallas Heart Study), and liver disease odds ratios of 1.13–1.23. Crucially, no association was found with hepatic triglyceride content, pointing specifically at glycogen as the culprit. This study explicitly identifies rs4841132 as being in complete LD with rs4240624 and uses both rsids to describe the same locus.

Hernaez et al. 2013⁶⁶ Hernaez et al. 2013
Hernaez R, McLean J, et al. "Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis." Clin Gastroenterol Hepatol, 2013 used NHANES III data (n=4,804) and found an OR of 1.28 (P=.03) for ultrasound-defined hepatic steatosis in non-Hispanic white adults — suggesting that glycogen accumulation in the liver may mimic the appearance of steatosis on standard ultrasound, even when triglycerides are not elevated.

The 2021 Männistö study (n=242 bariatric surgery patients) found that risk-allele carriers produced dramatically different bile acid profiles and that 13 of 17 bile lipid classes were elevated in carriers — a pattern that mirrors bile composition in gallstone patients.

Practical Actions

The primary lever for managing hepatic glycogen burden is dietary carbohydrate quality and quantity. The liver processes dietary carbohydrates — and especially fructose — almost exclusively, making this the highest-impact dietary modification for A-allele carriers. Prioritize low-glycemic carbohydrate sources (vegetables, legumes, lentils, barley) over refined carbohydrates and added sugars. Minimize fructose from sugary beverages, fruit juice, and high-fructose sweeteners.

Annual liver enzyme monitoring (ALT/AST) is warranted for heterozygous carriers; homozygous AA carriers should pursue a more thorough evaluation including discussion of hepatic imaging. Mildly elevated ALT in the absence of alcohol use or obesity should be flagged as potentially related to hepatic glycogen accumulation.

Gallstone risk is elevated for A-allele carriers, particularly in the context of obesity or planned rapid weight loss, which can mobilize bile cholesterol and precipitate stone formation.

Interactions

rs4841132 and rs4240624 are in complete LD and represent the same functional signal at the PPP1R3B locus. Carrying risk alleles at this locus is expected to have additive effects with PNPLA3 rs738409 (hepatic fat accumulation via a distinct lipid pathway) and GCKR rs780094 (impaired hepatic glucose sensing and elevated triglycerides). Individuals with risk alleles across these three genes face compounding liver stress through glycogen overload (PPP1R3B), lipid dysregulation (PNPLA3), and altered glucose metabolism (GCKR).

Methionine synthase (MTR) sits at the center of the one-carbon metabolism cycle, converting homocysteine¹¹ homocysteine
Homocysteine: a sulfur-containing amino acid that is neurotoxic and cardiovascularly damaging when it accumulates; it must be recycled back to methionine or cleared via the transsulfuration pathway back into methionine using methylcobalamin (active B12) as a cofactor and 5-methylTHF (methylfolate) as the methyl donor. This reaction is critical for two reasons: it clears homocysteine and regenerates methionine, which is then converted to S-adenosylmethionine (SAM)²² S-adenosylmethionine (SAM)
SAM: the universal methyl donor for DNA methylation, histone methylation, and hundreds of other methyltransferase reactions critical to gene regulation and development, the cell's primary methyl donor for epigenetic regulation.

rs10925239 is a deep intronic variant in the MTR gene — it lies within intron sequence and does not alter the protein. Its importance comes from a 2020/2021 study linking it to reduced risk of nonsyndromic cleft lip with or without cleft palate³³ nonsyndromic cleft lip with or without cleft palate
Nonsyndromic cleft lip/palate (NSCL/P): the most common craniofacial birth defect, affecting approximately 1 in 700 births worldwide. "Nonsyndromic" means it occurs in isolation without other malformations (NSCL/P), one of the most common craniofacial birth defects.

The Mechanism

Intronic variants can influence gene function by modulating splicing efficiency, mRNA stability, or transcription factor binding at regulatory elements embedded within introns. For rs10925239, the Salamanca et al. study found that the protective G allele is associated with reduced MTR expression — meaning the G allele appears to act as a cis-regulatory⁴⁴ cis-regulatory
Cis-regulatory: affecting the expression of the gene on the same chromosome, as opposed to trans-regulatory effects on other chromosomes variant that slightly dampens MTR transcription.

This creates a counterintuitive picture: lower MTR expression is apparently protective against cleft development. The authors hypothesize this may reflect subtle changes in SAM flux — when MTR is modestly downregulated, the cell's methyl group budget may shift in ways that alter the epigenetic landscape during the critical window of palate closure. Craniofacial development is exquisitely sensitive to one-carbon metabolism status, as evidenced by the longstanding protective effect of periconceptional folate on cleft risk.

The exact molecular mechanism has not been characterized for this specific variant. It likely acts as a tag SNP⁵⁵ tag SNP
Tag SNP: a variant in linkage disequilibrium with a nearby functional variant — it marks the same haplotype block as the causal variant even if it is not itself causal in linkage disequilibrium with a nearby regulatory element or splice signal.

The Evidence

The primary evidence comes from a Chilean case-control study⁶⁶ Chilean case-control study
Salamanca C et al. Genetic variants in S-adenosyl-methionine synthesis pathway and nonsyndromic cleft lip with or without cleft palate in Chile. Pediatric Research, 2021 of 234 NSCL/P cases and 309 controls examining 18 SNPs across SAM synthesis pathway genes. Of the variants tested, three deep intronic MTR SNPs showed significant protective effects after multiple-testing correction (q-value threshold): rs10925239 (OR 0.68, p=0.0032, q=0.0192), rs10925254 (OR 0.66), and rs3768142 (OR 0.66). All three shared the same direction of effect and correlated with reduced MTR expression in database annotations.

Two contextual lines of evidence support biological plausibility. A study by Fofou-Caillierez et al.⁷⁷ Fofou-Caillierez et al.
Fofou-Caillierez MB et al. Vitamin B-12 and liver activity and expression of methionine synthase are decreased in fetuses with neural tube defects. Am J Clin Nutr, 2019 found that MTR activity, mRNA, and protein expression were all significantly reduced in fetal livers from neural tube defect cases (p=0.001, 0.016, and 0.003 respectively), and that SAM levels correlated tightly with MTR activity and B12 status — confirming that MTR expression directly governs SAM availability during fetal development. A folate pathway study⁸⁸ folate pathway study
Blanton SH et al. Folate pathway and nonsyndromic cleft lip and palate. Birth Defects Res A, 2011 by Blanton et al. found MTR association with cleft risk specifically in Hispanic populations, along with gene-gene interactions in the methionine arm of one-carbon metabolism.

Notably, a meta-analysis⁹⁹ meta-analysis
Lei W et al. Associations between MTR A2756G, MTRR A66G, and TCN2 C776G polymorphisms and risk of NSCL/P: a meta-analysis. Genet Test Mol Biomarkers, 2018 of 12 studies found the coding variant MTR A2756G (rs1805087) shows no association with NSCL/P (pooled OR 0.95, p=0.55). This null result for the coding variant, combined with the positive finding for intronic variants, suggests the NSCL/P association may be driven specifically by regulatory effects on MTR expression rather than by the enzyme's catalytic function per se.

The evidence for rs10925239 is emerging — a single case-control study, population- limited to Chile, with no independent replication yet published. SNPedia assigns a magnitude of 3.0, reflecting a documented but not yet replicated association.

Practical Actions

Because only the T allele (risk) homozygotes carry a meaningfully elevated NSCL/P association, and this is an intronic variant affecting gene expression rather than enzyme function, the practical implications are modest. Carriers of T alleles should ensure optimal B12 and folate status — active forms preferred — particularly women planning pregnancy given the craniofacial development window. Monitoring homocysteine as a functional readout of the overall methylation cycle is the most actionable and evidence-based step.

This variant does not alter MTR enzyme kinetics directly; any management approach is focused on ensuring the methylation cycle has adequate substrate supply.

Interactions

rs10925239 sits in the same gene as the better-characterized MTR A2756G variant (rs1805087). Both influence the MTR pathway, but through different mechanisms — the coding variant alters enzyme activity while rs10925239 may alter expression levels. The sister intronic variant rs10925260 has a separate (NTD) association. Upstream, MTHFR (rs1801133, rs1801131) controls the methylfolate supply that MTR depends on, and MTRR (rs1801394) reactivates oxidized B12 between MTR reaction cycles. Carriers of variants across multiple points in this triad have compounded risk for methylation insufficiency.

Among the first genes implicated in type 2 diabetes by genome-wide association studies, the HHEX/IDE locus¹¹ HHEX/IDE locus
Hematopoietically Expressed Homeobox / Insulin- Degrading Enzyme — two neighboring genes on chromosome 10q23 with distinct roles in beta-cell biology has been replicated across dozens of populations and hundreds of thousands of participants. The SNP rs1111875 is the primary tag marker for this locus — in complete linkage disequilibrium (r²=1) with rs5015480 — and serves as the alternative genotyped position for this signal on consumer chips and whole-genome sequencing platforms that capture rs1111875 but not rs5015480.

The Mechanism

HHEX encodes a homeodomain transcription factor expressed in the liver, thyroid, and — critically — the developing pancreas. During embryogenesis, HHEX is required for proper formation of the ventral pancreatic bud; animal knockout models lacking HHEX fail to form a normal pancreas and show severe deficits in insulin-producing beta-cell mass. In adult beta cells, HHEX continues to regulate genes governing beta-cell identity and insulin gene expression programs.

The C allele at rs1111875 is associated with reduced HHEX expression in pancreatic tissue. The consequence is a diminished beta-cell secretory capacity and, specifically, a blunted first-phase insulin response²² first-phase insulin response
The rapid insulin burst in the first 10 minutes after a glucose load — this pulse is critical for suppressing post-meal blood glucose and is characteristically impaired in pre-diabetes and early T2D. The nearby IDE gene encodes insulin-degrading enzyme, which degrades secreted insulin and may further modulate circulating insulin levels, though whether HHEX or IDE is the primary causal gene at this locus remains under investigation.

The Evidence

rs1111875 has been studied as the lead marker for the HHEX/IDE locus across multiple independent GWAS and replication cohorts since 2007.

The landmark Sladek et al. 2007 Nature GWAS³³ Sladek et al. 2007 Nature GWAS
Sladek R et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature, 2007 identified the IDE-KIF11-HHEX region as one of four novel T2D risk loci in a French case-control cohort of 392,935 SNPs. The Scott et al. 2007 FUSION study⁴⁴ Scott et al. 2007 FUSION study
Scott LJ et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science, 2007 confirmed HHEX among validated T2D susceptibility loci with a per-C-allele OR of ~1.13 (p = 5.7 × 10⁻¹⁰) in combined European cohorts.

The Grarup et al. 2007 Danish cohort⁵⁵ Grarup et al. 2007 Danish cohort
Grarup N et al. Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects. Diabetes, 2007 provided direct functional evidence: the C allele was strongly associated with lower acute insulin response during an oral glucose tolerance test and with decreased insulin release after intravenous tolbutamide injection in young healthy subjects, implicating impaired beta-cell function specifically.

A meta-analysis by Wang et al. 2011⁶⁶ meta-analysis by Wang et al. 2011
Wang Y et al. Quantitative assessment of the influence of hematopoietically expressed homeobox variant (rs1111875) on type 2 diabetes risk. Mol Genet Metab, 2011 pooled 26 studies encompassing 110,875 subjects and confirmed the per-C-allele OR of 1.16 (95% CI 1.13–1.20). A larger Li et al. 2012 PLoS One meta-analysis⁷⁷ Li et al. 2012 PLoS One meta-analysis
Li X et al. Hematopoietically-expressed homeobox gene three widely-evaluated polymorphisms and risk for diabetes: a meta-analysis. PLoS One, 2012 extended this to 49 studies (57,931 cases, 74,658 controls), yielding an identical per-allele OR of 1.16. Both meta-analyses document significant ethnic heterogeneity — the C allele runs at ~58% in Europeans but only ~18% in East Asian populations, where the TT protective genotype predominates (~68% frequency).

Practical Implications

The HHEX/IDE locus impairs T2D risk through the insulin secretion axis — specifically reduced beta-cell mass and blunted first-phase insulin output — rather than the insulin resistance axis. This has direct dietary implications: beta cells with reduced secretory capacity are less able to handle large, rapid glucose loads. Spreading carbohydrate intake across meals, choosing lower-glycemic-index foods, and pairing carbohydrates with protein and fat all directly reduce the demand on first-phase insulin secretion.

Periodic metabolic monitoring (fasting glucose, HbA1c) is particularly valuable for this genotype because the first-phase secretory impairment is precisely what blunts early post-meal glucose suppression and progressively loads beta-cell reserve over decades.

Interactions

rs1111875 is in complete LD (r²=1) with rs5015480 — both tag the same functional signal at the HHEX/IDE locus. Carrying risk alleles at both this locus (impaired secretion) and at TCF7L2 rs7903146 (impaired Wnt-mediated beta-cell function) compounds T2D risk through converging but mechanistically independent pathways. Similarly, co-inheritance with SLC30A8 rs13266634 (zinc transporter affecting insulin granule crystallization) further loads the insulin secretion pathway. Individuals with risk alleles at multiple secretion-pathway loci should prioritize metabolic monitoring and glycemic-load management.

The chromosome 17q21 locus is the most consistently replicated genetic risk region for childhood-onset asthma. The locus spans a dense 130-kb regulatory haploblock containing six genes — IKZF3, ZPBP2, GSDMB, ORMDL3, LRRC3C, and GSDMA — and harbors a cluster of correlated variants that collectively regulate ORMDL3 expression in airway tissue and immune cells. rs11650680 is an intronic regulatory variant within this haploblock that was identified alongside rs7216389 in the original landmark GWAS¹¹ original landmark GWAS
Moffatt et al. Nature 2007, 994 childhood asthma cases vs 1,243 controls; rs11650680 and rs7216389 were among the top index SNPs at 17q21, p<10⁻¹². Unlike rs7216389 (where T is the risk allele), rs11650680 has the C allele as the risk allele and the T allele as the protective variant — a subtle but important distinction established by multiple meta-analyses.

The Mechanism

rs11650680 sits within an intron of the ORMDL3/GSDMB locus and functions as a regulatory eQTL²² regulatory eQTL
expression quantitative trait locus — a variant that alters nearby gene transcript levels without changing the protein sequence; rs11650680 modulates ORMDL3 and GSDMB expression in a C-allele-dose-dependent manner. The C allele is associated with higher ORMDL3 expression in airway epithelial cells and lymphoblastoid cell lines. Elevated ORMDL3 inhibits serine palmitoyltransferase, reducing de novo ceramide and sphingolipid synthesis in the airway epithelium. This sphingolipid deficit lowers T-cell activation thresholds, promotes Th2-skewed immune polarization, and activates the ATF6 branch of the unfolded protein response — collectively amplifying the eosinophilic airway inflammation that characterises asthma.

The T allele, by contrast, is associated with lower ORMDL3 expression³³ lower ORMDL3 expression
the T allele at rs11650680 reduces the C-allele-driven regulatory signal, producing less ORMDL3 mRNA in airway tissue and immune cells, and corresponds to the lowest asthma susceptibility at this locus. Carriers of one or two T alleles (CT and TT genotypes) produce less ORMDL3 and show correspondingly lower markers of airway eosinophilic inflammation than CC homozygotes.

The Evidence

The Shi et al. 2015 meta-analysis⁴⁴ Shi et al. 2015 meta-analysis
13 published case-control studies, 6,462 asthma cases and 7,357 controls; fixed-effects model; rs11650680 T allele significantly protective in dominant model (TT+CT vs. CC) established the asthma-protective role of the T allele across multiple populations. A second meta-analysis pooling 18 studies and 7,904 cases with 10,874 controls⁵⁵ pooling 18 studies and 7,904 cases with 10,874 controls
Wan et al. Human Immunology 2014, rs11650680 and rs12603332 T alleles both protective, consistent across Caucasian and Asian subgroups replicated the finding.

Population-specific data reveals important variation. A study of 315 Chinese children (315 asthma cases, 192 controls; Leung et al. Allergy 2009)⁶⁶ (315 asthma cases, 192 controls; Leung et al. Allergy 2009)
rs11650680 significantly associated with asthma diagnosis, atopy, and total plasma IgE levels (p=0.008–0.0002) in Chinese children; the CC risk genotype correlated with higher IgE burden and atopic sensitisation demonstrated that the rs11650680 locus affects not only asthma diagnosis but also atopic sensitisation and IgE production — linking the variant to the broader Th2-driven atopic phenotype beyond asthma alone.

In Japanese women, the CT heterozygous genotype was significantly inversely associated with asthma⁷⁷ CT heterozygous genotype was significantly inversely associated with asthma
Miyake et al. DNA Cell Biol 2014, 202 asthma cases and 1,290 controls in the KOMCHS cohort; CT vs. CC OR 0.67 (95% CI 0.46–0.96); effect was specific to adult-onset asthma, consistent with the meta-analysis direction. Separately, Acosta-Perez et al. 2012⁸⁸ Acosta-Perez et al. 2012
JACI, Puerto Rican and Mexican children; CC genotype associated with higher eosinophil-associated biomarkers and bronchial hyperresponsiveness, consistent with elevated ORMDL3-driven eosinophilic inflammation extended the finding to Latino populations.

Practical Implications

The CC genotype is the most common globally (~69%) and represents the reference state for this variant — but it also carries elevated asthma susceptibility. For CC individuals with asthma, the clinical picture is one of elevated eosinophilic airway inflammation driven by increased ORMDL3 activity: monitoring FeNO and blood eosinophil counts helps characterize the inflammatory endotype and guide treatment. For TT and CT carriers, the T allele provides partial to complete attenuation of the ORMDL3-driven airway inflammatory signal.

The rs11650680 signal is partially correlated with rs7216389 and rs12936231, and these SNPs likely tag overlapping but not fully redundant regulatory elements within the 17q21 haploblock. Carrying the protective T allele at rs11650680 does not eliminate risk conferred by other 17q21 variants, so the broader haploblock context matters for a complete risk picture.

Interactions

rs11650680 lies in strong LD with rs7216389 and rs12936231 within the same 17q21 haploblock, but the LD is incomplete — some individuals carry discordant genotypes across these three SNPs, suggesting partially independent regulatory signals. The combination of the CC genotype at rs11650680, the TT genotype at rs7216389, and the CC genotype at rs12936231 represents full engagement of the ORMDL3-overexpressing regulatory state; individuals with this haplotype combination have the highest ORMDL3 expression and the greatest airway inflammatory burden. The 17q21 locus also shows a well-documented inverse relationship with autoimmune disease risk⁹⁹ inverse relationship with autoimmune disease risk
the asthma-risk haplotype (high ORMDL3) is associated with lower risk of type 1 diabetes and Crohn's disease; the autoimmune-risk allele at rs2872507 is protective for asthma — reflecting the Th1/Th17 vs. Th2 immune axis trade-off.

About one in three people is highly susceptible to motion sickness. For decades this variation was assumed to be mostly psychological or a matter of inner-ear anatomy, but the first genome-wide association study of motion sickness¹¹ first genome-wide association study of motion sickness
Hromatka et al. Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis. Human Molecular Genetics, 2015 — in 80,494 individuals from 23andMe — showed the difference is partly genetic, and one of the strongest signals sits inside NLGN1, the gene that builds neuroligin 1.

rs11713169 is an intronic variant within NLGN1 on chromosome 3 (3q26.31). The C allele reached genome-wide significance (P = 5.9×10⁻¹³, beta = 0.052) for increased motion sickness susceptibility. The C allele is present in about 15% of Europeans and only 3% of Africans; roughly 75% of people globally carry two A alleles and have no elevated genetic susceptibility from this locus.

The Mechanism

Neuroligin 1²² Neuroligin 1
NL1, encoded by NLGN1, is a postsynaptic transmembrane cell adhesion protein found exclusively at excitatory (glutamatergic) synapses. Its extracellular domain binds presynaptic β-neurexins³³ β-neurexins
a family of presynaptic cell adhesion molecules that form the trans-synaptic bridge required for synapse formation and maturation, creating the structural bridge that recruits and aligns NMDA and AMPA receptors at the postsynaptic density.

Wu et al. 2019⁴⁴ Wu et al. 2019
Neuroligin-1 Signaling Controls LTP and NMDA Receptors by Distinct Molecular Pathways. Neuron demonstrated that NL1 performs two mechanistically separate functions: its intracellular domain maintains baseline NMDA receptor levels at the synapse, while its trans-synaptic neurexin interaction is required for NMDA-dependent long-term potentiation (LTP) and dendritic spine expansion. Deleting NL1 abolishes the structural plasticity associated with LTP. This places NL1 directly at the intersection of synapse maintenance and activity-dependent learning.

Motion sickness habituation — the process by which the brain learns to suppress nausea responses after repeated exposure to provocative motion — requires exactly this kind of NMDA-dependent synaptic plasticity. Vestibular nucleus neurons undergo NMDA receptor-driven CREB activation and upregulate inhibitory GABAA receptors⁵⁵ Vestibular nucleus neurons undergo NMDA receptor-driven CREB activation and upregulate inhibitory GABAA receptors
Wang et al. 2012, Brain Research during repeated rotation training, while hippocampal CA1 encodes the stored motion pattern via CaMKII/CREB signaling⁶⁶ hippocampal CA1 encodes the stored motion pattern via CaMKII/CREB signaling
Wang et al. 2017, Scientific Reports — allowing the nervous system to anticipate rather than react to familiar motion. NLGN1 variation that subtly alters NMDA-dependent plasticity at excitatory synapses throughout these circuits is a plausible mechanism for the observed genetic effect on habituation efficiency.

The Evidence

The signal at rs11713169 emerged from the Hromatka et al. 2015 GWAS⁷⁷ Hromatka et al. 2015 GWAS
Human Molecular Genetics of 80,494 individuals — the first and largest genetic study of motion sickness ever conducted. The study identified 35 SNPs at genome-wide significance (P < 5×10⁻⁸), and rs11713169 was among the strongest hits (P = 5.9×10⁻¹³). The authors grouped associated genes into three categories: balance and vestibular development (PVRL3, TSHZ1), neurological processes including central habituation (NLGN1), and glucose homeostasis. The study also documented sex-specific effects, with up to three times stronger genetic effects in women than men at some loci.

The evidence for NL1's specific molecular role in excitatory synaptic plasticity is substantial and converges from multiple independent laboratories and model systems, supporting the mechanism by which intronic NLGN1 variation would modulate motion sickness susceptibility through altered synaptic plasticity efficiency in vestibular and hippocampal circuits.

Practical Actions

Motion sickness has effective management strategies that work independently of genotype — but knowing you carry the C allele provides a biological reason to invest in them proactively. H1-antihistamines (dimenhydrinate, meclizine) are the primary pharmacological option; they block histaminergic vestibular-cerebellar signalling that amplifies the sensory-mismatch response.

Habituation remains the most effective non-pharmacological approach⁸⁸ Habituation remains the most effective non-pharmacological approach
Keshavarz & Golding 2022, Current Opinion in Neurology. Graded exposure — beginning with mild motion and progressively increasing challenge over days to weeks — builds the stored internal motion model in hippocampal circuits. An important caveat: medications that suppress symptoms during exposure can slow habituation. If your goal is long-term adaptation rather than single-event relief, graded unmedicated exposure is more effective than relying on antihistamines.

Interactions

The GWAS that identified rs11713169 also found rs10514168 (near TSHZ1) as a motion-sickness locus via vestibular development pathways. Both variants contribute additively to susceptibility through different mechanisms — rs10514168 via inner-ear development and rs11713169 via central synaptic habituation. Carrying risk alleles at both loci further elevates baseline susceptibility.

Sex modifies the effect: the Hromatka study found effects up to three times stronger in women at some motion-sickness loci. Whether rs11713169 specifically shows a sex-stratified effect was not individually reported for this variant.

Peroxisome proliferator-activated receptor gamma (PPARγ) is the master transcriptional regulator of fat cell development and a central node in insulin sensitivity¹¹ insulin sensitivity
PPARγ activates hundreds of genes controlling fatty acid uptake, lipid storage, and glucose homeostasis in adipose tissue, liver, and muscle. rs1175543 is a common intronic variant in PPARG — one of several non-coding variants across the gene that tag functional haplotypes influencing downstream metabolic risk.

The Mechanism

rs1175543 sits deep in intron 9 of PPARG at GRCh38 chr3:12,424,933 (A>G substitution). It does not change any amino acid. Instead, its relevance is primarily as a haplotype marker: it is in strong linkage disequilibrium²² strong linkage disequilibrium
Linkage disequilibrium (LD) means two variants are so physically close on the chromosome that they are nearly always inherited together; D'=97 indicates near-complete co-inheritance with rs709158 (D' = 0.97) and with rs1797912 and rs12490265, forming a haplotype block that may influence PPARγ expression, splicing efficiency, or enhancer activity in metabolically active tissues. The precise regulatory mechanism has not been characterized at the molecular level, but intronic PPARG variants in this block have been shown to affect adipogenesis-related gene networks in population studies.

The Evidence

A case-control study in 489 Kazakh subjects³³ case-control study in 489 Kazakh subjects
Guo et al. Analysis of the haplotype and linkage disequilibrium of PPARγ gene polymorphisms rs3856806, rs12490265, rs1797912, and rs1175543 among patients with metabolic syndrome in Kazakh of Xinjiang Province. Genet Mol Res, 2014 found that the rs1175543 G allele frequency was significantly lower in metabolic syndrome patients than in controls (40.61% vs 47.54%, P = 0.029), suggesting that G carriers are less likely to develop metabolic syndrome. The AGCC haplotype (incorporating rs1175543G) emerged as a protective factor.

A large prospective cohort study in Washington County, Maryland⁴⁴ prospective cohort study in Washington County, Maryland
Gallicchio et al. Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality. PPAR Res, 2008 tracked 9,364 Caucasian participants for over a decade and found a significant age-adjusted association between rs1175543 and baseline total cholesterol levels. No association with cardiovascular events or all-cause mortality was detected over the follow-up period, suggesting the variant's influence is metabolic rather than directly cardiovascular.

The evidence for rs1175543 as an independent functional variant is emerging: the metabolic syndrome association derives from a single study in one ethnic group, and the cholesterol signal has not been replicated in a separate large-scale GWAS. The variant's biological significance is best understood as part of the broader PPARG haplotype block rather than as a stand-alone risk allele.

Practical Actions

Carriers of the G allele — particularly GG homozygotes — appear to have a modestly favorable metabolic profile compared to AA homozygotes. For AA carriers, the modest risk signal at this locus is best addressed through interventions known to support PPARγ pathway health: managing dietary fat composition and monitoring key metabolic markers that track insulin-related risk.

Interactions

rs1175543 is in very strong LD with rs709158 and moderate LD with rs1797912 and rs12490265 — all intronic PPARG variants. These SNPs collectively form a haplotype block, and the protective haplotypes (AGCC, GAAT) appear to confer a combined effect greater than any single variant alone. rs1175543 should always be interpreted alongside the canonical PPARG Pro12Ala variant (rs1801282), which has established evidence for insulin sensitivity effects. Carriers of both the AA genotype at rs1175543 and the CC genotype at rs1801282 (Pro/Pro) accumulate the most PPARG-related metabolic risk across this gene.

Apolipoprotein B (apoB) is the structural backbone of every LDL, VLDL, and chylomicron particle your liver makes. Without a full-length apoB-100, your liver cannot build and secrete normal LDL particles, so your circulating LDL cholesterol stays characteristically and permanently low¹¹ characteristically and permanently low
Heterozygous FHBL carriers almost always have LDL-C below 70 mg/dL regardless of diet, a lifelong trait caused by the variant, not by healthy lifestyle. This sounds like good news — and for cardiovascular health, it mostly is — but the same impaired lipid-export machinery creates two clinically relevant risks: fat accumulation in the liver and impaired transport of fat-soluble vitamins.

The Mechanism

The R2522X variant introduces a premature stop codon at amino acid 2,522 of the 4,536-amino-acid apoB-100 protein (c.7564C>T on the coding strand; G>A on the GRCh38 plus strand). The resulting truncated protein — called apoB-55²² apoB-55
The "55" refers to the fact that the truncated protein is approximately 55% the length of full-length apoB-100 — comprises about 55% of the normal protein length and is secreted at roughly 37–40% of the normal molar rate compared to wild-type apoB-100, consistent with the linear relationship between truncation length and secretion efficiency demonstrated by Parhofer et al.³³ demonstrated by Parhofer et al.
Parhofer et al. Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate. J Lipid Res, 1996. The half of the protein that is missing includes domains critical for maximal lipid recruitment into the lipoprotein particle core.

Because apoB is the only structural protein on LDL particles, each cell carries one normal APOB allele and one truncating allele. The liver produces both full-length apoB-100 and the shorter apoB-55, but the truncated version carries less lipid cargo per particle, and fewer lipid-laden particles leave the liver — so hepatocytes accumulate triglycerides that cannot be exported.

The Evidence

The R2522X variant was first identified in the early 1990s in patients with unexplained low cholesterol. The same CGA→TGA change at the CpG dinucleotide hot spot in exon 26 was later independently rediscovered in a second kindred by Gabelli et al.⁴⁴ Gabelli et al.
Gabelli et al. Diabetes mellitus in a new kindred with familial hypobetalipoproteinemia and an apolipoprotein B truncation (apoB-55). Atherosclerosis, 1998, whose proband had LDL-C of 44 mg/dL and detectable plasma apoB-55 on immunoblotting. Notably, the proband and his father both had type 2 diabetes, yet neither had clinically manifest macrovascular complications — consistent with the cardiovascular-protective effect of lifelong low LDL-C.

The apoB-55 truncation falls in a zone where the protein can still be secreted and detected in plasma (unlike very short truncations below ~apoB-30, which are not detectable in plasma at all). Its secretion efficiency of ~37% of normal means heterozygotes lose roughly a third of their normal VLDL export capacity, explaining the 3-to-5-fold increase in hepatic fat content that characterizes FHBL, as reviewed by Schonfeld⁵⁵ Schonfeld
Schonfeld G. Familial hypobetalipoproteinemia: a review. J Lipid Res, 2003.

A systematic literature review by Molk et al.⁶⁶ Molk et al.
Molk et al. Non-alcoholic fatty liver disease in a pediatric patient with heterozygous familial hypobetalipoproteinemia due to a novel APOB variant. Front Med, 2023 confirms that fatty liver disease occurs even in heterozygous carriers and can present in childhood. About 5–10% of heterozygous FHBL individuals develop more severe nonalcoholic steatohepatitis requiring medical attention.

Practical Actions

For heterozygous carriers the most important immediate step is establishing a baseline: a fasting lipid panel confirms the expected low LDL-C and rules out concurrent dyslipidemia; liver enzymes (AST/ALT) and a hepatic ultrasound screen for steatosis; and serum levels of vitamins A, D, E, and K evaluate fat-soluble vitamin status. Because apoB-containing lipoprotein particles are the primary carriers of fat-soluble vitamins from the gut into circulation, impaired VLDL/chylomicron secretion can subtly reduce vitamin transport even when dietary intake is adequate. Supplementation with water-dispersible or emulsified forms of vitamins D, E, A, and K corrects any measured deficiency efficiently.

Dietary saturated fat restriction is not the goal here (unlike APOE4) — in fact, very low fat diets can worsen fat-soluble vitamin absorption. The aim is identifying and correcting any subclinical deficiency before it causes neurological or ophthalmological consequences.

Cardiovascular risk is paradoxically reduced: lifelong LDL-C below 70 mg/dL confers protection against atherosclerosis, and carriers need not take statins for lipid-lowering purposes. However, the reduced LDL does not protect against the metabolic consequences of obesity or insulin resistance, so maintaining a healthy metabolic profile remains relevant.

Interactions

In the rare case of a compound heterozygote or homozygote for APOB loss-of-function variants, the phenotype resembles abetalipoproteinemia (severe fat malabsorption, acanthocytosis, retinitis pigmentosa, progressive ataxia). Interaction with APOE genotype (rs429358, rs7412) is worth noting conceptually: APOE4 would ordinarily raise LDL cholesterol, but an APOB truncating variant overrides this by limiting the number of LDL particles produced rather than their clearance rate. The net effect in a double carrier would still be low LDL-C, driven by impaired production.

While most pharmacogenomic attention focuses on loss-of-function variants, the CYP2C19*17 allele¹¹ rs12248560 represents the opposite end of the spectrum: a gain-of-function variant that increases enzyme activity beyond normal levels. This variant sits in the promoter region and upregulates CYP2C19 gene expression.

The Mechanism

The rs12248560 variant²² C>T at position -806 in the promoter region alters a transcription factor binding site in the CYP2C19 promoter, increasing gene expression by approximately 2-fold. More enzyme means faster metabolism of all CYP2C19 substrates. Homozygous carriers (TT) are classified as ultrarapid metabolizers, while heterozygous carriers (CT) are rapid metabolizers. The variant was first characterized by Sim et al. in 2006³³ Sim et al. in 2006
Sim SC et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism. Clin Pharmacol Ther, 2006.

Clinical Implications

For proton pump inhibitors (PPIs), rapid and ultrarapid metabolizers break down the drug too quickly, potentially leading to inadequate acid suppression. Standard PPI doses may not effectively control acid reflux or heal ulcers. Higher doses or alternative medications may be needed. The CPIC guideline for PPIs⁴⁴ CPIC guideline for PPIs
Lima JJ et al. CPIC guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther, 2021 recommends increasing PPI doses by 50-100% for ultrarapid metabolizers.

For clopidogrel, increased CYP2C19 activity is actually beneficial because more prodrug gets converted to the active metabolite, enhancing the antiplatelet effect. However, this could theoretically increase bleeding risk.

The Diplotype Complexity

Your overall CYP2C19 status depends on the combination of both alleles. Someone carrying *2/*17 (one loss-of-function, one gain-of-function) presents a classification challenge - current guidelines generally classify this as intermediate metabolizer status, though the clinical impact may vary by medication.

Practical Considerations

If you are a rapid or ultrarapid metabolizer, pay attention to PPI effectiveness. If standard doses of omeprazole or pantoprazole do not adequately control your acid reflux symptoms, your CYP2C19 genotype may be the reason. Discuss with your doctor about dose adjustments or alternative acid-suppressing medications that are not CYP2C19 substrates.

Nucleobindin-2 (NUCB2) encodes the precursor protein that is proteolytically cleaved to release nesfatin-1¹¹ nesfatin-1
An 82-amino acid neuropeptide that suppresses appetite and modulates energy balance via melanocortin MC3/MC4 receptors and CRF2 — operates independently of the leptin pathway, a neuropeptide with broad roles in appetite suppression, glucose regulation, sleep-wake cycling, and — more recently discovered — cancer biology. The rs1330 variant sits within an intron of NUCB2 on chromosome 11 (GRCh38 position 17,294,482), meaning it does not alter the nesfatin-1 amino acid sequence directly. Instead, its effects are regulatory: the T allele is thought to influence NUCB2 splicing efficiency, transcript stability, or expression levels, though the precise molecular mechanism has not yet been resolved.

The T allele is the minor allele in most populations (~30–39% frequency globally, with notably lower frequency in African populations at ~17%). The reference C/C genotype represents wild-type nesfatin-1 expression; T allele carriers show associations across multiple disease contexts with a consistent direction — higher risk — though with sex-specific patterns that suggest hormonal context shapes how this intronic variant exerts its effects.

The Mechanism

As an intron variant, rs1330 does not change the nesfatin-1 peptide sequence. Its regulatory impact is inferred from its population-level associations. The T allele may alter the efficiency of RNA splicing at one of NUCB2's five transcript variants, reduce mRNA stability, or affect transcription factor binding in an intronic regulatory element — any of which would reduce the amount of functional NUCB2 protein available for cleavage into nesfatin-1. Reduced circulating nesfatin-1 is the common downstream consequence observed in obesity and insulin-resistant states across multiple NUCB2 studies, and the rs1330 T allele likely compounds this deficiency via a cis-regulatory mechanism.

The sex-specific pattern observed in the Zegers et al. obesity study²² Zegers et al. obesity study
Zegers D et al. Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. Mol Genet Metab, 2011 — where rs1330 associated with obesity only in males — and the reciprocal Li et al. T2D finding³³ Li et al. T2D finding
Li XS et al. NUCB2 polymorphisms are associated with an increased risk for type 2 diabetes in the Chinese population. Endocr Connect, 2020 in females (OR 1.31–1.42) may reflect estrogen and androgen modulation of NUCB2 expression. Estrogen upregulates nesfatin-1 production in certain hypothalamic circuits, potentially masking the effect of a reduced-expression variant in pre-menopausal women while leaving males more exposed to its impact on appetite and energy balance.

The Evidence

Obesity (males). The Zegers et al. 2011⁴⁴ Zegers et al. 2011
Zegers D et al. Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. Mol Genet Metab, 2011 case-control study genotyped 1,049 obese and 315 normal-weight Caucasian subjects across eight NUCB2 tagSNPs. Three variants — rs1330, rs214101, and rs757081 — showed association with obesity protection, but only in the male sub-analysis. Linear regression further linked rs1330 to BMI, body weight, and fat-free mass in men. This was the first evidence that NUCB2 intronic variants influence energy homeostasis in humans.

Type 2 diabetes (females). A Chinese Han study by Li et al. (2020)⁵⁵ Li et al. (2020)
Li XS et al. NUCB2 polymorphisms are associated with an increased risk for type 2 diabetes in the Chinese population. Endocr Connect, 2020 genotyped 578 T2DM patients against 1,609 healthy controls and identified rs1330 as significantly associated with T2DM risk in women (OR 1.31–1.42, P<0.05). The variant was also correlated with BMI in the female subpopulation, suggesting its influence spans both adiposity and glucose metabolism in women. No association was detected in men in this cohort — the reverse sex-specificity pattern from the Zegers obesity data.

Colorectal cancer. A Mexican cross-sectional study by Macías-Gómez et al. (2025)⁶⁶ Macías-Gómez et al. (2025)
Macías-Gómez NM et al. Variants in the neuropeptide gene NUCB2 as a possible biomarker for colorectal cancer. 2025 enrolled 397 CRC patients and 383 healthy controls. The TT genotype at rs1330 was significantly associated with colorectal cancer (OR 2.66, P<0.001), while CT heterozygotes showed an apparent protective pattern (OR 0.61), an unusual non-additive effect possibly reflecting over-dominant heterozygote advantage. Hardy-Weinberg deviation in the CRC group, however, warrants cautious interpretation.

Oral cancer. A Taiwanese cohort study by Yu et al. (2026)⁷⁷ Yu et al. (2026)
Yu CC et al. Association of NUCB2 genetic variants with the clinicopathological features of oral cancer. 2026 examined four NUCB2 polymorphisms in men with oral cancer. Compared to C/C wild-type, carriage of at least one T allele at rs1330 was associated with elevated risk of disease progression to stage III/IV, particularly in patients aged ≥60 years.

Sleep biology. rs1330 has not been studied directly in sleep GWAS, but the parent gene's sleep-regulatory role is established. In rat models, Vas et al. (2013)⁸⁸ Vas et al. (2013)
Vas S et al. Nesfatin-1/NUCB2 as a potential new element of sleep regulation in rats. PLoS One, 2013 demonstrated that central nesfatin-1 reduces REM sleep and increases wakefulness, and that hypothalamic NUCB2 expression declines during REM sleep deprivation and rebounds during recovery. Any NUCB2 variant that reduces nesfatin-1 output may therefore modulate sleep architecture, though this remains inferred biology at the rs1330 level.

Practical Implications

For CT and TT carriers, the most actionable implications are in metabolic monitoring and cancer awareness. Given the sex-specific patterns — obesity/BMI associations in males, T2D risk in females — sex-targeted monitoring is appropriate. Dietary interventions that support nesfatin-1 release, particularly high-protein morning meals, are theoretically beneficial but are based on functional biology rather than rs1330-specific trial data.

Interactions

rs1330 was identified in the same study (Zegers et al. 2011) as rs757081 and rs214101 — all three intronic and coding variants in NUCB2 showed male-specific obesity associations together, suggesting they may function as a regulatory haplotype influencing total NUCB2/nesfatin-1 output. Combined carriage of rs1330 T allele and rs757081 C allele (the obesity-risk form at the missense position) may additively reduce effective nesfatin-1 activity through both regulatory and protein-level mechanisms.

The interleukin-23 receptor (IL23R) gene encodes a key checkpoint in adaptive immunity. When IL-23 binds IL23R on T helper 17 (Th17) cells, it triggers STAT3 phosphorylation¹¹ STAT3 phosphorylation
STAT3 is a transcription factor that, once activated, drives production of the inflammatory cytokines IL-17A and IL-22, sustaining chronic inflammation in the gut, spine, and skin. The rs1343151 variant sits in an intron of IL23R at chromosome 1 position 67,253,446 (GRCh38) and carries no direct amino acid change. Its clinical significance comes from two distinct properties: it tags the protective IL23R haplotype that dampens Th17 responses in ankylosing spondylitis (AS) and inflammatory bowel disease (IBD), and it carries an independent association with rheumatoid arthritis (RA) susceptibility that operates through a separate biological mechanism.

The Mechanism

As an intronic variant, rs1343151 does not directly alter the IL-23 receptor protein. Instead, it acts as a tag SNP²² tag SNP
a variant that is inherited together with nearby functional variants so frequently that knowing its allele predicts those of its neighbours; here rs1343151 co-inherits with rs11465804 and the functional missense variant rs11209026 (R381Q) for the AS and IBD associations. The biological engine is the R381Q substitution at rs11209026: replacing arginine with glutamine at position 381 in the cytoplasmic tail of IL23R partially uncouples the receptor from JAK2/STAT3 signalling, reducing IL-17A output in Th17 effector cells from approximately 36 pg/ml to 5.5 pg/ml under IL-23 stimulation — a 6.5-fold reduction.

The RA association, by contrast, appears to be at least partially independent of the R381Q haplotype. Hollis-Moffatt et al. 2009³³ Hollis-Moffatt et al. 2009
Ann Rheum Dis; 3,000+ Caucasian RA cases and 3,800+ controls found no association of rs11209026 with RA (OR 1.01) while rs1343151 showed an OR of 1.14 in the same dataset — an unusual dissociation that suggests rs1343151 is tagging a different regulatory element or haplotype block for RA than for IBD and AS.

The Evidence

For Crohn's disease and ulcerative colitis, the protective effect of the A allele is well-replicated in European populations. A New Zealand cohort study (Ferguson et al. 2011⁴⁴ (Ferguson et al. 2011
Gastroenterol Res Pract; 339 CD cases, 407 controls) found an allelic OR of 0.68 (P=0.001), with AA homozygotes showing an OR of 0.29 (95% CI 0.16–0.53) relative to GG individuals — a striking 71% reduction in CD odds. A subsequent meta-analysis of 15 studies⁵⁵ meta-analysis of 15 studies
Ding et al. Sci Rep 2015 confirmed this with a pooled OR of 0.725 (95% CI 0.690–0.763) across Caucasian populations. Notably, no protective signal was detected in Asian populations, consistent with the low A allele frequency in East Asian cohorts (~8%).

For ankylosing spondylitis, a meta-analysis of 25 case-control studies⁶⁶ meta-analysis of 25 case-control studies
Zhong et al. Expert Rev Clin Immunol 2018; 8,431 AS cases, 8,972 controls confirmed that the A allele frequency was significantly lower in AS patients than controls (P<0.001), ranking rs1343151 among four IL23R polymorphisms with consistent protective signals against AS. The study-level OR for rs1343151 in an earlier meta-analysis of ankylosing spondylitis cohorts was approximately 0.68 (95% CI 0.55–0.83).

For rheumatoid arthritis, the picture reverses: the A allele is associated with a modest increase in RA risk (OR ~1.11–1.14 in Caucasians), which has been independently replicated across multiple cohorts. This disease-direction reversal at the same allele — protective for gut and spine inflammation, risky for synovial inflammation — reflects the differential roles of IL-23/Th17 signalling in different tissue compartments and disease pathologies.

Practical Implications

For individuals concerned about IBD or spondyloarthritis, the A allele at rs1343151 is a protective marker. AA homozygotes have substantially lower lifetime odds of Crohn's disease and ankylosing spondylitis than GG homozygotes, in parallel with other IL23R protective variants. For RA, the relationship inverts — carriers of the A allele have slightly elevated susceptibility. However, the absolute risk difference conferred by this single variant for RA is small (OR ~1.11) compared with the protective effect on IBD and AS (OR ~0.68–0.72). IL-23 pathway targeting (with biologics such as risankizumab or guselkumab) is highly effective for AS and CD; carriers of the GG genotype at rs1343151 — lacking the protective haplotype — may be among those most likely to benefit from such therapies if they develop these conditions.

Interactions

rs1343151 is in moderate-to-strong linkage disequilibrium with several other IL23R variants on chromosome 1p31.3, including rs11465804, rs10489629, and the functional missense variant rs11209026 (R381Q). For the IBD and AS associations, these variants are largely interchangeable as they tag the same protective haplotype block; a person carrying the protective A allele at rs1343151 will almost always also carry the protective alleles at rs11465804 and rs10489629.

The RA signal at rs1343151, being independent of rs11209026, represents a distinct haplotype association and likely reflects different regulatory architecture in synovial versus intestinal/entheseal immune environments. The IL23R susceptibility variants rs2201841 and rs1004819 tag a separate, risk-conferring haplotype block and are tracked individually in this database.